Citadel Advisors’s GALENA BIOPHARMA INC COM RXII Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2016
Q4 | – | Sell |
-79,800
| Closed | -$28K | – | 8376 |
|
|
2016
Q3 | $28K | Buy |
79,800
+25,300
| +46% | +$8.88K | ﹤0.01% | 6979 |
|
|
2016
Q2 | $25K | Buy |
54,500
+10,400
| +24% | +$4.77K | ﹤0.01% | 6556 |
|
|
2016
Q1 | $60K | Buy |
44,100
+18,400
| +72% | +$25K | ﹤0.01% | 6207 |
|
|
2015
Q4 | $38K | Sell |
25,700
-3,700
| -13% | -$5.47K | ﹤0.01% | 7519 |
|
|
2015
Q3 | $46K | Buy |
29,400
+7,800
| +36% | +$12.2K | ﹤0.01% | 7651 |
|
|
2015
Q2 | $37K | Sell |
21,600
-400
| -2% | -$685 | ﹤0.01% | 7868 |
|
|
2015
Q1 | $31K | Sell |
22,000
-13,000
| -37% | -$18.3K | ﹤0.01% | 7692 |
|
|
2014
Q4 | $53K | Sell |
35,000
-32,800
| -48% | -$49.7K | ﹤0.01% | 7155 |
|
|
2014
Q3 | $140K | Sell |
67,800
-41,600
| -38% | -$85.9K | ﹤0.01% | 6084 |
|
|
2014
Q2 | $335K | Buy |
109,400
+51,000
| +87% | +$156K | ﹤0.01% | 4912 |
|
|
2014
Q1 | $146K | Buy |
58,400
+15,900
| +37% | +$39.8K | ﹤0.01% | 5831 |
|
|
2013
Q4 | $211K | Buy |
42,500
+13,600
| +47% | +$67.5K | ﹤0.01% | 4976 |
|
|
2013
Q3 | $66K | Buy |
28,900
+4,000
| +16% | +$9.13K | ﹤0.01% | 5621 |
|
|
2013
Q2 | $55K | Buy |
+24,900
| New | +$55K | ﹤0.01% | 5620 |
|
Citadel Advisors's RXII Position: Q4 2016 in Review
Citadel Advisors sold out of GALENA BIOPHARMA INC COM (RXII) in Q4 2016, closing a stake of 47,821 shares — an estimated $17K sold.
Citadel Advisors first reported a position in RXII in Q2 2013 and held it in 13 quarters. The position peaked at $284K in Q1 2014. 0 funds tracked by Wall St. Rank hold RXII as of Q4 2016.
- Citadel Advisors reported no remaining GALENA BIOPHARMA INC COM position as of Q4 2016 after selling out during the quarter.
- Citadel Advisors sold 47,821 GALENA BIOPHARMA INC COM shares in Q4 2016, an estimated $17K.
- Citadel Advisors first reported a position in GALENA BIOPHARMA INC COM in Q2 2013 and held it in 13 quarters.
- Citadel Advisors's GALENA BIOPHARMA INC COM position peaked at $284K in Q1 2014.
- 0 funds tracked by Wall St. Rank held GALENA BIOPHARMA INC COM as of Q4 2016.
Based on Citadel Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.